^
Association details:
| Biomarker: | PD-1 elevation |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Regimen: | (vincristine + Rituxan (rituximab) + doxorubicin hydrochloride + prednisone + cyclophosphamide + etoposide IV) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Soluble PD-1 but Not PD-L1 Levels Predict Poor Outcome in Patients with High-Risk Diffuse Large B-Cell Lymphoma
Published date:
01/22/2021
Excerpt:
Patients with high pretreatment sPD-1 levels (highest third, “high sPD-1 group”) had significantly worse outcomes than patients with low pretreatment sPD-1 levels (lowest two-thirds, “low sPD-1 group”) (five-year OS 78% vs. 91%, p = 0.021; five-year PFS 73% vs. 89%, p = 0.016; Figure 4)...The patients were treated with biweekly rituximab, cyclophosphamide, doxorubicin, etoposide, and prednisone (R-CHOEP) immunochemotherapy...
DOI:
10.3390/cancers13030398
Trial ID:
